Biotech IV Monitor

LBPH — Longboard Pharmaceuticals Inc.

Acquired by Lundbeck · December 2024
Longboard Pharmaceuticals Inc. was acquired by Lundbeck in December 2024. LBPH no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Lundbeck, and their dates may not have been updated since.

Clinical trial readout dates for Longboard Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts22 Phase 3

Upcoming readouts

Phase 3 LP352
Dravet Syndrome · NCT06660394
December 2026
Ongoing
Phase 3 LP352
Developmental and Epileptic Encephalopathy · NCT06908226
November 2027
Enrolling

Companies working on similar indications

Discussion

No messages yet. If you follow LBPH, you can start the conversation.
Contact — questions or corrections about LBPH: dukeupt@gmail.com